Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Clifford Hospital, Guangzhou, China

Status and phase

Unknown

Phase 2

Phase 1

Conditions

Carcinoma, Non-Small-Cell Lung

Treatments

Drug: Tyrosine kinase inhibitor

Drug: Vitamin C

Study type

Interventional

Funder types

Other

Identifiers

NCT03799094

2/2018-19

Details and patient eligibility

About

This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC patients.

Full description

The effects of vitamin C in combination with tyrosine kinase inhibitor on tumor size, tumor markers, inflammatory factor levels, quality of life, duration of resistance, progression-free survival, and overall survival time were evaluated.

This trial is a low risk treatment, and has developed the appropriate safety measures and contingency plans to ensure patients' safety in the whole process.

Patients will be followed up after the end of the trial, and follow-up observations will be performed every month during the first year. Followed every 3 months in the second year for 3 years.

Enrollment

150 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Primary non-small cell lung cancer (adenocarcinoma) with EGFR mutations on exons 19 and 21.
18 years old to 75 years old.
During the trial, patients were prescribed TKI drugs(received initial treatment within 2 months, or change medication within 2 months) and did not receive chemotherapy or radiotherapy at the same time.
Eastern Cooperative Oncology Group (ECOG) performance status are 0 to 2.
Expected survival over 3 months.
Household registration is Guangdong Province.

Exclusion criteria

Co-morbid conditions that affect survival: end stage congestive heart failure, unstable angina, myocardial infarction (within the past 6 weeks), and uncontrolled blood sugars of greater than 300 mg/dL, known chronic active hepatitis or cirrhosis.
Glucose-6-phosphate dehydrogenase deficiency (G6PD) (a relative contraindication).
Patients who are allergic to vitamin C.
Patients with HIV and other infectious diseases.
Patients who are taking anticoagulants and have coagulopathy;
Combine dysfunction of important organs such as heart, lung, liver and kidney;
Patients with impaired renal function (serum creatinine content > 1.2 mg/dL)
Compromised liver function with evidence of Serum total bilirubin content, Serum alanine aminotransferase(ALT) and aspartate transaminase(AST)> 2 times normal reference value.
Pregnant or lactating female.
Smoking and alcohol abuse patients;
Anti-infective treatment is required for systemic or localized serious infections;
Patients with hyperuricacidemia (normal: 91-456 μmol / 24h (8-40mg / 24h));
Wilson's disease.
Evidence of significant psychiatric disorder by history or examination that would prevent completion of the study or preclude informed consent.
Any condition that impairs the patients' ability to swallow, which impairs drug absorption or drug kinetic parameters, including any kind of gastrointestinal resection or surgery;
History of surgery of visceral organs within 6 weeks before the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

150 participants in 2 patient groups

Experimental group

Description:

75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.

Treatment:

Drug: Tyrosine kinase inhibitor

Drug: Vitamin C

Control group

Experimental group

Description:

75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)

Treatment:

Drug: Tyrosine kinase inhibitor

Trial documents